Keyphrases
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
100%
High-risk Human Papillomavirus (HR-HPV)
65%
Denmark
53%
Head-and-neck Cancer
39%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
34%
Population-based Study
26%
Mesenchymal Stromal Cells
25%
Meta-analysis
25%
Overall Survival
24%
Systematic Meta-analysis
22%
Cancer Patients
21%
Mesenchymal Stem Cell Therapy
19%
Xerostomia
19%
Incidence Rate
18%
Danish Population
18%
Age-specific Incidence
18%
Radiation-induced Xerostomia
16%
5-year Survival
16%
Head-and-neck
15%
Radiation Effects
15%
Embase
15%
HPV+
14%
Tumor
14%
PubMed
14%
Population-based
13%
Thyroid Cancer
12%
Adipokinetic Hormone
12%
Relative Survival
12%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
11%
Pediatric
11%
Human Papillomavirus DNA
11%
HPV Positive
11%
Increased Incidence
10%
Comorbidity
10%
Older Adults
10%
Salivary Gland Diseases
10%
Hazard Ratio
10%
Patient Characteristics
9%
Children with Cancer
9%
Salivary Gland Cancer
9%
Liquid Biopsy
9%
Second Primary Cancer
9%
Stem Cell Therapy
9%
Oral Cavity Cancer
9%
Treatment Initiation
9%
Average Annual Percent Change
8%
Cancer Mortality
8%
Placebo
8%
Confidence Interval
8%
Hyposalivation
8%
Medicine and Dentistry
Wart Virus
69%
Oropharynx Squamous Cell Carcinoma
66%
Systematic Review
65%
Oropharyngeal Cancer
44%
Overall Survival
31%
Squamous Cell Carcinoma
28%
Xerostomia
28%
Neoplasm
26%
Meta-Analysis
25%
Oral Cavity
23%
Head and Neck Cancer
23%
P16
22%
Recurrent Disease
21%
Pediatrics
20%
Malignant Neoplasm
20%
Disease
19%
Oral Cancer
18%
Neck
16%
Thyroid Cancer
15%
Mesenchymal Stem Cell
14%
Salivary Gland
13%
Mouth Squamous Cell Carcinoma
13%
Mesenchymal Stem Cell Transplantation
12%
Stromal Cell
12%
Placebo
12%
Prevalence
11%
Adipose Tissue
11%
Relative Survival
11%
Case-Control Study
10%
Diagnosis
9%
Salivation
9%
Retrospective Study
9%
Hazard Ratio
9%
Second Cancer
9%
Pediatric Cancer
9%
Liquid Biopsy
9%
Symptom
9%
Cancer
9%
Radiation Therapy
8%
Proportional Hazards Model
8%
Recurrence Free Survival
7%
Hyposalivation
7%
Human Papillomavirus Type 16
7%
Time to Treatment
6%
Stem Cell Therapy
6%
Patient Characteristics
6%
Survival Rate
6%
Quality of Life
6%
Neck Mass
6%
Soft Tissue Sarcoma
6%